The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | The correlation between JAK2v617f molecular response and EFS in patients with early PV
Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, discusses the findings of an analysis assessing the relationship between JAK2v617f molecular response (MR) and event-free survival (EFS) in patients with early polycythemia vera (PV) who were newly diagnosed and/or did not have resistance to hydroxyurea. Patients were treated with ropeginterferon-alfa2b or hydroxyurea as part of the PROUD-PV and CONTINUATION-PV trials (NCT01949805 and NCT02218047, respectively). Those patients who exhibited depletion of JAK2V617F mutated cells with treatment experienced an improved EFS compared to those who did not achieve an MR. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
